“I think we should all be pretty selective in whom we're operating on in the metastasectomy setting,” says Harras B. Zaid, MD.
In this video, Harras B. Zaid, MD, discusses sequencing surgery and systemic therapy in patients with renal cell carcinoma, which was discussed during a session at SUO titled, “Panel Discussion: Salvage Therapies for Recurrence Following Local Therapy (Ablation, Systemic Therapy, XRT, Surgery).” Zaid is an assistant professor in the department of surgery and perioperative care at the University of Texas, Austin and a urologic oncologist at Dell Seton Medical Center.
Video Transcript:
Thinking about patients who present with metastatic disease and they have their primary tumor intact, if there's a certain list of criteria, at least in my practice, where I assess their candidacy for undergoing a cytoreductive nephrectomy. Is surgery feasible? Is there going to be a potential oncologic or symptomatic benefit? And is it in lines with what the patient wants? There's a component of shared discussion. But generally speaking, patients who have large volume metastatic disease at presentation who have visceral metastatic disease, for example, liver mets, and those who have a poor performance status, I'm usually going to defer upfront surgery. In those patients, a biopsy of either the primary or metastatic site is what I would recommend if they have a site that's metastatic and biopsy can be obtained. I usually prefer a biopsy of the metastatic sites; it's not always feasible. Then, engage our medical oncology colleagues with regards to initiation of systemic treatment.
Their specific case scenarios where radiation oncology may be involved. For example, a patient who has a locally advanced renal cell carcinoma with a large tumor thrombus, engaging them to discuss the role of SBRT, at least in palliation and keeping the tumor thrombus from getting larger. More common for me now, and I think other urologists do favor upfront systemic treatment, especially as those treatments have gotten better in metastatic renal cell carcinoma.
Now, when it comes to patients who have been treated with nephrectomy and then develop a delayed metastasis, the sequencing of systemic treatment vs surgery, again, depends on the sites of metastases, the number of metastases, patient's performance status, and feasibility of metastasectomy. I think we should all be pretty selective in whom we're operating on in the metastasectomy setting. It should be feasible without significant undue harm or risk, and also with the understanding that even with metastasectomy, surgically resecting a metastatic lesion, many of these patients will relapse and may need systemic treatment.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.